CD44v6 expression is associated with a poor prognosis in Chinese hepatocellular carcinoma patients: A meta-analysis - 14/12/15
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background |
The role of CD44v6 in hepatocellular carcinoma (HCC) remains controversial. To clarify the association of CD44v6 with survival in HCC, we performed a meta-analysis of the literature with meta-analysis.
Methods |
Trials were selected for further analysis if they provided an independent assessment of CD44v6 in HCC and reported the survival data in the context of CD44v6 status. Sensitivity analyses were conducted using the patient's disease stage, IHC cut-off value, and ethnicity.
Results |
A total of nine trials, which comprised 942 patients, were included in the meta-analysis. The combined hazard ratio (HR) of 2.13 [95% CI, 1.58–2.88; test for heterogeneity P=0.061] suggests that high CD44v6 expression has an impact on patient survival. When the studies were restricted to Chinese patients, high levels of CD44v6 expression were correlated with reduced survival (HR 2.27, 95% CI=1.79–2.86; P=0.544 for heterogeneity). In addition, the heterogeneity disappeared when the analysis was restricted to Chinese.
Conclusion |
CD44v6 expression is associated with poor prognosis for Chinese HCC patients.
Le texte complet de cet article est disponible en PDF.Plan
Vol 39 - N° 6
P. 736-739 - décembre 2015 Retour au numéro
Article précédent
- Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands
- Lydia G.M. van der Geest, Suzanne van Meer, Janina G.H. Schrier, Jan N.M. Ijzermans, Heinz-Josef Klümpen, Karel J. van Erpecum, Rob A. de Man
- Helicobacter pylori in celiac disease and in duodenal intraepithelial lymphocytosis: Active protagonist or innocent bystander?
- Daniele Simondi, Davide Giuseppe Ribaldone, Gabriele Antonio Bonagura, Simona Foi, Nicoletta Sapone, Marco Garavagno, Vincenzo Villanacci, Davide Bernardi, Rinaldo Pellicano, Mario Rizzetto, Marco Astegiano
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?